1. Home
  2. Publications
  1. Home
  2. Publications

Filters

Research Groups

Core Facilities

Start date
End date

Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis.
Authors: JM Winfield, JC Wakefield, JD Brenton, K AbdulJabbar, A Savio, S Freeman, E...
Research group: Brenton Group
E-pub date: 1 Mar 2021
Journal name: Br J Cancer

Maturation Block in Childhood Cancer.
Authors: S Behjati, RJ Gilbertson, SM Pfister
Research group: Gilbertson Group
E-pub date: 1 Mar 2021
Journal name: Cancer Discov

Atypical Neurogenesis in Induced Pluripotent Stem Cells From Autistic Individuals.
Authors: D Adhya, V Swarup, R Nagy, L Dutan, C Shum, EP Valencia-Alarcón, KM Jozwik...
Research group: Carroll Group
E-pub date: 1 Mar 2021
Journal name: Biol Psychiatry

Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).
Authors: A Gajjar, GW Robinson, KS Smith, T Lin, TE Merchant, M Chintagumpala, A Mah...
Research group: Gilbertson Group
E-pub date: 1 Mar 2021
Journal name: J Clin Oncol

Combinatorial CRISPR screen identifies fitness effects of gene paralogues.
Authors: NA Thompson, M Ranzani, L van der Weyden, V Iyer, V Offord, A Droop, F Beha...
Research group: Jackson Group
E-pub date: 26 Feb 2021
Journal name: Nat Commun

TET2 is a component of the estrogen receptor complex and controls 5mC to 5hmC conversion at estrogen receptor cis-regulatory regions.
Authors: R Broome, I Chernukhin, S Jamieson, K Kishore, EK Papachristou, S-Q Mao, CG...
Research group: Proteomics, Carroll Group, Balasubramanian Group
E-pub date: 23 Feb 2021
Journal name: Cell Rep

Inhibitor of Differentiation 4 (ID4) represses mammary myoepithelial differentiation via inhibition of HEB.
Authors: H Holliday, D Roden, S Junankar, SZ Wu, LA Baker, C Krisp, C-L Chan, A McFa...
Research group: Carroll Group
E-pub date: 19 Feb 2021
Journal name: iScience

Multi-modal imaging of high-risk ductal carcinoma in situ of the breast using C2Am: a targeted cell death imaging agent.
Authors: Z Szucs, J Joseph, TJ Larkin, B Xie, SE Bohndiek, KM Brindle, AA Neves
Research group: , Bohndiek Group
E-pub date: 17 Feb 2021
Journal name: Breast Cancer Res